InvestorsHub Logo
Followers 32
Posts 4258
Boards Moderated 0
Alias Born 07/25/2007

Re: None

Friday, 05/29/2020 4:23:58 PM

Friday, May 29, 2020 4:23:58 PM

Post# of 977
New TRIL data from ASCO. Here is the link to the poster. The data is a monotherapy dose escalation of TRIL's second anti-CDC47 blocker drug TTI-622. The trial is listed as also having combination arms too therapy but no mention of them here. Looks promising as FTSV's anti-CD47 drug which fueled their buyout at $6 billion didn't show any ORR as a monotherapy.

https://s22.q4cdn.com/183592819/files/ASCO-2020-TTI-622-01-Poster-FINAL.pdf